RxDoctor Payments Data

Ana Recober-Montilla, MD

Neurology · Wynnewood, PANPI 1710971023

Payments from drug & device makers

$11,657in general payments, 2019–2025

Across 333 payments — averaging $35.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Pfizer$471
  • Upsher-smith Laboratories LLC$441
  • Amgen$248
  • Teva Pharmaceuticals USA, Inc.$170
  • Sunovion Pharmaceuticals Inc.$166
  • plus $2K from 35 others

What the payments were for

  • Consulting fees$5,40046%
  • Food & beverage$6,21553%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,657 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$210,912
Medicare patients
183
Services billed
20,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate140$276,770
UbrelvyUbrogepant64$113,989
Emgality SyringeGalcanezumab-Gnlm34$42,115
Emgality PenGalcanezumab-Gnlm45$37,073
Ajovy AutoinjectorFremanezumab-Vfrm28$27,282
QuliptaAtogepant15$23,676
Aimovig AutoinjectorErenumab-Aooe15$16,798
Ajovy SyringeFremanezumab-Vfrm12$10,034
Eletriptan HbrEletriptan Hydrobromide70$3,997
Sumatriptan Succinate115$3,287
Gabapentin137$1,910
RizatriptanRizatriptan Benzoate126$1,889
Naratriptan Hcl82$1,837
Nortriptyline Hcl20$706
Oxcarbazepine23$697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$471$276,770140 claims
AbbVieUbrelvy, Qulipta$8,012$137,66579 claims
Upsher-smith Laboratories LLCTopiramate$441$26826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →